Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05337241 · ClinicalTrials.gov registry record · NA
Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT
A NA study of Refractory Ventricular Tachycardia, sponsored by Thermedical.
- Recruiting
- Registry status
- NA
- Development phase
- 130
- Enrollment target
- 7
- Study locations
NCT05337241: Recruiting NA study of Refractory Ventricular Tachycardia, sponsored by Thermedical.
NCT05337241 is a NA study of Refractory Ventricular Tachycardia that is actively recruiting participants, run by Thermedical. The registered enrollment target is 130 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05337241, a NA study of Refractory Ventricular Tachycardia, is actively recruiting participants, sponsored by Thermedical.
- RECRUITING
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
- 7
- Study locations
Study Summary
The Thermedical Ablation System and Durablate catheter is indicated for use in patients with recurrent, sustained, monomorphic ventricular tachycardia (SMVT) refractory to drug therapy and conventional (approved) catheter ablation. Subjects with recurrent, SMVT refractory to drug therapy and conventional catheter ablation who are not eligible for, or will not likely benefit from repeat endocardial ablation using an approved catheter.
Primary Outcome
Percentage of target clinical VTs that are non-inducible at end of the study ablation procedure (if PES performed at procedure conclusion)
Conditions Studied
Interventions
- DEVICE Saline Enhanced Radiofrequency (SERF) Ablation
Study Locations (7)
Quebec
- Montreal Heart Institute - Institut de Cardiologie de Montréal - Montreal
- Quebec Heart and Lung Institute - Institut universitaire de cardiologie et de pneumologie de Québec - Québec
Alabama
- University of Alabama at Birmingham - Birmingham
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
South Carolina
- Medical University of South Carolina - Charleston
Tennessee
- Vanderbilt University Medical Center - Nashville
Utah
- Intermountain Healthcare - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-08-09 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05337241 shows while recruiting
NCT05337241 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Refractory Ventricular Tachycardia appearing as the primary indexed condition, and to 1 intervention - of which Saline Enhanced Radiofrequency (SERF) Ablation is the first listed.
NCT05337241 lists 7 locations in 6 states (Quebec, Alabama, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT05337241 about?
NCT05337241 is a clinical study titled "Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT". The Thermedical Ablation System and Durablate catheter is indicated for use in patients with recurrent, sustained, monomorphic ventricular tachycardia (SMVT) refractory to drug therapy and conventional (approved) catheter ablation. Subjects with recurrent, SMVT refractory to drug therapy and conven...
What is the current status of trial NCT05337241?
This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2025-08-09. Estimated completion is 2027-06-30.
What conditions does trial NCT05337241 study?
This clinical trial studies the following conditions: Refractory Ventricular Tachycardia.
What interventions are being tested in trial NCT05337241?
The interventions under investigation include: Saline Enhanced Radiofrequency (SERF) Ablation (DEVICE).
Who is sponsoring clinical trial NCT05337241?
This trial is sponsored by Thermedical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05337241 being conducted?
This trial has 7 study locations across Alabama, Pennsylvania, South Carolina, Tennessee, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05337241's enrollment target sits among peer trials
130 733rd of 2000 higher than 1,258 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI